Transplanted ER+ TC11 cells provide an immunocompetent model to investigate the interactions of estrogen inhibition, ICIs, and RT in aggressive ER+ breast cancer (Additional file 2: Fig. S1Ai, ii) [26]. The gene discussed is ESR1; the disease is breast carcinoma.